{"disease":{"id":"hospital-acquired-pneumonia","name":"Hospital Acquired Pneumonia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:31:21.551Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":1,"trial_count":0},"drugs":{"marketed":[{"drug_id":"zavicefta-ceftazidime-avibactam","indication_name":"Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible bacteria.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zavicefta, Ceftazidime-Avibactam","generic_name":"zavicefta-ceftazidime-avibactam","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Bacterial cell wall synthesis","drug_class":"Cephalosporin antibiotic and beta-lactamase inhibitor combination","quality_score":55,"revenue":"638","mechanism":""},{"drug_id":"relebactam","indication_name":"Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Recarbrio","generic_name":"RELEBACTAM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Renal Dehydropeptidase Inhibitor [EPC]","quality_score":34,"revenue":null,"mechanism":"Recarbrio works by inhibiting the beta-lactamase enzymes produced by certain bacteria, allowing carbapenem antibiotics to effectively target and kill the bacteria."},{"drug_id":"durlobactam","indication_name":"Hospital-acquired Bacterial Pneumonia (HABP)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xacduro (Copackaged)","generic_name":"DURLOBACTAM","company_name":"Entasis Therap","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor","quality_score":45,"revenue":null,"mechanism":"Xacduro works by binding to and inhibiting bacterial beta-lactamases, allowing antibiotics to effectively kill bacteria."},{"drug_id":"sulbactam","indication_name":"Hospital-acquired bacterial pneumonia caused by acinetobacter baumannii-calcoaceticus complex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"SULBACTAM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine beta-lactamase-like protein LACTB, mitochondrial","drug_class":"beta Lactamase Inhibitor","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"durlobactam","indication_name":"Hospital-acquired bacterial pneumonia caused by acinetobacter baumannii-calcoaceticus complex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xacduro (Copackaged)","generic_name":"DURLOBACTAM","company_name":"Entasis Therap","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor","quality_score":45,"revenue":null,"mechanism":"Xacduro works by binding to and inhibiting bacterial beta-lactamases, allowing antibiotics to effectively kill bacteria."}],"pipeline":[{"drug_id":"ceftazidime-avibactam-group","indication_name":"Hospital Acquired Pneumonia","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ceftazidime avibactam group","generic_name":"ceftazidime-avibactam-group","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Non-Interventional Study","quality_score":10,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":5,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03361085","title":"Modular Prevention Bundle for Non-ventilator-associated Hospital-acquired Pneumonia (nvHAP)","phase":"NA","overall_status":"TERMINATED","enrollment_count":45000,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT06028217","title":"Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":4000,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT05060718","title":"HOspital NEtwork STudy - Preparation for a Randomized Evaluation of Anti-Pneumonia Strategies","phase":"","overall_status":"COMPLETED","enrollment_count":2165,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT05979545","title":"EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":1900,"lead_sponsor_name":"National University of Singapore","has_results":false},{"nct_id":"NCT03348579","title":"Hospital-acquired Pneumonia in Intensive Care Unit","phase":"","overall_status":"COMPLETED","enrollment_count":1850,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT07004049","title":"Optimising TREATment for Severe Gram-Negative Bacterial Infections","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"National University of Singapore","has_results":false},{"nct_id":"NCT05733104","title":"A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05914584","title":"\"Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":450,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT06269900","title":"Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT05204563","title":"Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":450,"lead_sponsor_name":"Evopoint Biosciences Inc.","has_results":true},{"nct_id":"NCT04937075","title":"Impact of Antimicrobial Stewardship on Outcomes of Patients With Hospital-acquired Pneumonia Due to Gram-negative Bacilli - A Before-after Study","phase":"","overall_status":"COMPLETED","enrollment_count":420,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT07011433","title":"Pneumonia Pathogens' Virulence Factors, Patient Inflammatory Markers, and Their Associations With Outcomes","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":300,"lead_sponsor_name":"Ruta Nutautiene","has_results":false},{"nct_id":"NCT06916481","title":"Definition of Sub-phenotypes of Pneumonia Based on the Respiratory Microbiome Composition to Predict Microbial and Clinical Treatment Failures","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03032380","title":"Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Shionogi","has_results":true},{"nct_id":"NCT06602934","title":"Long-term Alterations of Host-microbiome Interactions and Cardiovascular and Respiratory Diseases Progression After Pneumonia","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT03583333","title":"Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":274,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT07326540","title":"Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":248,"lead_sponsor_name":"BioVersys SAS","has_results":false},{"nct_id":"NCT04774094","title":"Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":235,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06867458","title":"Steriwave ICU Pilot Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":227,"lead_sponsor_name":"Fraser Health","has_results":false},{"nct_id":"NCT05483309","title":"Feasibility Study of Contemporary Diagnostics for Patients With Suspected Hospital-Acquired Pneumonia.","phase":"NA","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"University of Liverpool","has_results":false},{"nct_id":"NCT05487586","title":"Real-World Study of Ceftazidime Avibactam in China","phase":"","overall_status":"TERMINATED","enrollment_count":220,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05624684","title":"Diagnostic Performance and Impact of a Multiplex PCR Pneumonia Panel in ICU Patients With Severe Pneumonia.","phase":"","overall_status":"COMPLETED","enrollment_count":210,"lead_sponsor_name":"Avicenna Military Hospital","has_results":false},{"nct_id":"NCT03894046","title":"Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":207,"lead_sponsor_name":"Entasis Therapeutics","has_results":true},{"nct_id":"NCT05877625","title":"Study on Dynamic Environmental Exposome of ICU and the Establishment of Microbial Transmission Model Between Environment and Host","phase":"","overall_status":"UNKNOWN","enrollment_count":180,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT02714595","title":"Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"Shionogi","has_results":true},{"nct_id":"NCT03439124","title":"Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":138,"lead_sponsor_name":"Basilea Pharmaceutica","has_results":true},{"nct_id":"NCT04700202","title":"Identifying Risk Factors for Gram-negative Resistance for HAP/VAP in the Intensive Care Unit","phase":"","overall_status":"COMPLETED","enrollment_count":132,"lead_sponsor_name":"Methodist Health System","has_results":false},{"nct_id":"NCT05905055","title":"P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Meiji Seika Pharma Co., Ltd.","has_results":false},{"nct_id":"NCT05952648","title":"HAP/VAP Diagnosis in Critically Ill Septic Patients Using a Multiplex PCR Array","phase":"NA","overall_status":"RECRUITING","enrollment_count":126,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT04153682","title":"Trial on a Strategy Combining Rapid Diagnostic Testing and Antimicrobial Stewardship to Improve Antibiotic Use in Patients With Hospital-acquired Pneumonia.","phase":"NA","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04403971","title":"0.12% Chlorhexidine Oral Care for the Prevention of Non-ventilator Hospital-acquired Pneumonia","phase":"NA","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"National Cheng-Kung University Hospital","has_results":false},{"nct_id":"NCT07268560","title":"Real-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CRE","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Sir Run Run Shaw Hospital","has_results":false},{"nct_id":"NCT04215991","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Shionogi","has_results":false},{"nct_id":"NCT03496220","title":"Effect of Angulus on Patient-elevation Compliance","phase":"NA","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Angulus, LLC","has_results":true},{"nct_id":"NCT01970371","title":"A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"Achaogen, Inc.","has_results":true},{"nct_id":"NCT04882085","title":"Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05785442","title":"Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Hellenic Institute for the Study of Sepsis","has_results":false},{"nct_id":"NCT04335539","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"Shionogi","has_results":true},{"nct_id":"NCT05663905","title":"Efficacy of Intravenous Amboxol Hydrochloride as an Adjunct Therapy for Severe Pneumonia in Critically Ill Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"National University of Malaysia","has_results":false}],"total":39},"guidelines":[],"source":"Drug Landscape verified database"}